Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core

被引:40
作者
Fevig, JM [1 ]
Pinto, DJ [1 ]
Han, Q [1 ]
Quan, ML [1 ]
Pruitt, JR [1 ]
Jacobson, IC [1 ]
Galemmo, RA [1 ]
Wang, SA [1 ]
Orwat, MJ [1 ]
Bostrom, LL [1 ]
Knabb, RM [1 ]
Wong, PC [1 ]
Lam, PYS [1 ]
Wexler, RR [1 ]
机构
[1] DuPont Pharmaceut Co, Wilmington, DE 19880 USA
关键词
D O I
10.1016/S0960-894X(01)00029-4
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The selective inhibition of coagulation factor Xa has emerged as an attractive strategy for the discovery of novel antithrombotic agents. Here we describe highly potent benzamidine factor Xa inhibitors based on a vicinally-substituted heterocyclic core. (C) 2001 DuPont Pharmaceuticals Company. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:641 / 645
页数:5
相关论文
共 15 条
[1]  
BASHA A, 1977, TETRAHEDRON LETT, P4171
[2]  
Ewing William R., 1999, Drugs of the Future, V24, P771, DOI 10.1358/dof.1999.024.07.858624
[3]  
Fevig JM, 1999, ANNU REP MED CHEM, V34, P81
[4]  
FEVIG JM, 1999, 217 NAT M AM CHEM SO
[5]  
GALEMMO RA, 2000, 220 NAT M AM CHEM SO
[6]  
KETTNER C, 1990, J BIOL CHEM, V265, P18289
[7]  
LAM PYS, 2000, 220 NAT M AM CHEM SO
[8]  
PINTO DJ, 1999, 217 NAT M AM CHEM SO
[9]   Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′- (methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa [J].
Pinto, DJP ;
Orwat, MJ ;
Wang, SG ;
Fevig, JM ;
Quan, ML ;
Amparo, E ;
Cacciola, J ;
Rossi, KA ;
Alexander, RS ;
Smallwood, AM ;
Luettgen, JM ;
Liang, L ;
Aungst, BJ ;
Wright, MR ;
Knabb, RM ;
Wong, PC ;
Wexler, RR ;
Lam, PYS .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (04) :566-578
[10]   Isoxazolines and isoxazoles as Factor Xa inhibitors [J].
Pruitt, JR ;
Pinto, DJ ;
Estrella, MJ ;
Bostrom, LL ;
Knabb, RM ;
Wong, PC ;
Wright, MR ;
Wexler, RR .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (08) :685-689